Fludarabine

Catalog No.S1491 Synonyms: FaraA, Fludarabinum

Fludarabine Chemical Structure

Molecular Weight(MW): 285.23

Fludarabine is a STAT1 activation inhibitor which causes a specific depletion of STAT1 protein (and mRNA) but not of other STATs. Also a DNA synthesis inhibitor in vascular smooth muscle cells.

Size Price Stock Quantity  
In DMSO USD 126 In stock
USD 97 In stock
USD 310 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 44 Publications

Purity & Quality Control

Choose Selective STAT Inhibitors

Biological Activity

Description Fludarabine is a STAT1 activation inhibitor which causes a specific depletion of STAT1 protein (and mRNA) but not of other STATs. Also a DNA synthesis inhibitor in vascular smooth muscle cells.
Targets
STAT1 [4]
(Vascular smooth muscle cells)
In vitro

Fludarabine efficiently inhibits the proliferation of RPMI 8226 cells with IC50 of 1.54 μg/mL. The IC50 of Fludarabine against MM.1S and MM.1R cells is 13.48 μg/mL and 33.79 μg/mL, respectively. In contrast, U266 cells are resistant to Fludarabine with IC50 of 222.2 μg/mL. Fludarabine treatment results in increased number of cells in the G1 phase of cell cycle, accompanied with a concomitant reduction of cells at the S phase of cell cycle in a time-dependent manner. Fludarabine induces a cell cycle block and triggers apoptosis in MM cells. Fludarabine triggers time-dependent cleavage of caspase-8, -9, and -3, -7, followed by PARP cleavage. Fludarabine increases expression of Bax in a time-dependent fashion, while the expression of Bak doesn't change. After exposure to Fludarabine for 12 hours, RPMI 8226 cells shows a loss of membrane potential with 61.05% of the cells expressing low fluorescence of rhodamine 123 compared with 8.62% of cells in untreated control. [1] To enhance solubility, Fludarabine is formulated as the monophosphate (F-ara-AMP, fudarabine), which is instantaneously and quantitatively dephosphorylated to the parent nucleoside upon intravenous infusion. Inside the cells rephosphorylation occurs which leads to fuoroadenine arabinoside triphosphate (F-ara-ATP), the major cytotoxic metabolite of F-ara-A. [2] Fludarabine can also induce pro-inflammatory stimulation of monocytic cells, as evaluated by increased expression of ICAM-1 and IL-8 release. [3] Fludarabine does not affect the growth of ovarian cancer cell lines, whereas it induces marked and dose-dependent inhibition of proliferation in melanoma cell lines. [4] Fludarabine induces significant reduction of STAT-1 phosphorylation, whereas it does not change JAK2 activation. Interestingly, Fludarabine does not significantly affect the phosphorylation of these three STAT proteins. Fludarabine (1.5 mg) significantly prevents STAT-1 phosphorylation and also reduces the increased amount of this protein. No significant changes are demonstrated in JAK2 phosphorylation at 2 days, but Fludarabine inhibits JAK2-increased expression at 7 days. Fludarabine specifically inhibits STAT-1 activation without affecting other STAT proteins and consequently diminishes VSMC proliferation. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Jeko-1  MkH6SpVv[3Srb36gRZN{[Xl? NUHYd4VLOjBizszN M2nmWlI1KGh? MlrqbY5pcWKrdIOg[ZhxemW|c3nvckBw\iCLRF:= M1zoU|I2QTRyN{Gy
MV-4-11 NWT6PIh1SXCxcITvd4l{KEG|c3H5 NFX4UYUzNjVizszN MUi0PEBp M3L1V4lv\HWlZYOgZZBweHSxc3nzJJNtcWeqdHz5 NEfscI8zPTFzMUW4Ny=>
THP-1 NVrpSnZ[SXCxcITvd4l{KEG|c3H5 M2mxWFIvPSEQvF2= NFThWG81QCCq MorObY5lfWOnczDhdI9xfG:|aYOgd4xq\2i2bIm= M{LiVVI2OTFzNUiz
MOLM 13 MmXiRZBweHSxc3nzJGF{e2G7 NHOyV40zNjVizszN MXK0PEBp M4\ib4lv\HWlZYOgZZBweHSxc3nzJJNtcWeqdHz5 M{jHR|I2OTFzNUiz
KBM3/Bu2506 Mn;XRZBweHSxc3nzJGF{e2G7 Mk\ONk42KM7:TR?= NX7sT|J{PDhiaB?= MXjpcoR2[2W|IHHwc5B1d3OrczDzcIlocHSueR?= NVuzWppiOjVzMUG1PFM>
Nalm-6 MorXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXXO29HUUN3ME2xPEDPxE1? NYfyUXNFOjVyNkGxNFE>
Reh NH3UUZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4SxRmlEPTB;M{Cg{txO MVGyOVA3OTFyMR?=
U2937 MkH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3KxRWlEPTB;MU[g{txO M4nZbVI2ODZzMUCx
Mec-1 M1Xi[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M16wfmlEPTExvK61NFAh|ryP NVPXZnNjOjVyNkGxNFE>
RPMI-8226 NXnrZ3J[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTiWHNUUUN3ME21NFAh|ryP MYqyOVA3OTFyMR?=
Molt-4 NXjCNXJOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTF6MDFOwG0> M3\i[VI2ODZzMUCx
Nalm-6-FluR M3HzOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7oTWM2OD1{NUCg{txO NFzWcWUzPTB4MUGwNS=>
Raji  MW\GeY5kfGmxbjDBd5NigQ>? Ml\EN:Kh|ryP NYfRd3dUOjRxNEivO|IhcA>? NUGxNZZzcW6mdXPld{Bi[2O3bYXsZZRqd26|IH;mJJA2OyxicE[zJIFv\CCyN{RCpC=> MUSyOFk1ODZ7NR?=
PBMC NFW4OmpHfW6ldHnvckBCe3OjeR?= MlK1OVAwOTByIN88US=> MkK1NlQhcA>? MmrCSG1UVw>? NID2Oo5qdmirYnn0d{BUXEGWMTDwbI9{eGixconsZZRqd25? NVrzXY55OjR7MUG4O|I>
MDA-231 Mo\tSpVv[3Srb36gRZN{[Xl? NG\6fmcyODBizszN MnSzNlQhcA>? MlrZSG1UVw>? Mlf3[IVkemWjc3XzJGlFVyCneIDy[ZN{cW:w M136PVI1QTFzOEey
624.38mel  NFHDc49HfW6ldHnvckBCe3OjeR?= MmDXOVAh|ryP MlvJNlQhcA>? MonBSG1UVw>? Mn\3[IVkemWjc3XzJGlFVyCneIDy[ZN{cW:w Mny1NlQ6OTF6N{K=
MDA-231 MV\GeY5kfGmxbjDBd5NigQ>? NG\NN|A2OC1{MECg{txO NInITFkzPCCq NEDYU2tFVVOR M1HPSolvcGmkaYTzJGlFVyCjY4Tpeol1gSCrbnTldIVv\GWwdHz5JI9nKG2UTlGgcIV3\Wy| MkT2NlQ6OTF6N{K=
624.38mel  Mor5SpVv[3Srb36gRZN{[Xl? Mn7TOVAuOjByIN88US=> NFz0fGozPCCq M1zsS2ROW09? NHnxbJdqdmirYnn0d{BKTE9iYXP0bZZqfHliaX7k[ZBmdmSnboTsfUBw\iCvUl7BJIxmfmWucx?= NIOzfZYzPDlzMUi3Ni=>
HMECs NWrUS2w6TnWwY4Tpc44hSXO|YYm= NUfFSpdZOTBywrFOwG3DqA>? MknDN|bDqGh? MoqwbY5pcWKrdIOgTWZP|rQEoHHu[EBNWFNiaX7keYNm\CCVVFHUNUBxcG:|cHjvdplt[XSrb36gZY5lKEmURkGg[ZhxemW|c3nvci=> MVGyOFIyOTN{Nx?=
HMECs  MXnGeY5kfGmxbjDBd5NigQ>? MV6xNFDDqM7:TdMg M3LNdVM3yqCq MVPpcohq[mm2czDJSm7PucLibXXkbYF1\WRicHjvd5Bpd3K7bHH0bY9vKG:oIGPURXQyKGGwZDDTWGFVOyxiYoX0JI5wfCCxZjDTWGFVOg>? M2\o[VI1OjFzM{K3
BJAB NX\ZR3FISXCxcITvd4l{KEG|c3H5 MmPkOeKh|ryP M1fneFI1KGh? NHixdWlqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NVPmN4xNOjRyNUexOFc>
I-83 NVzoW|dUSXCxcITvd4l{KEG|c3H5 NX3pd202PcLizszN NGPLWWEzPCCq MmLjbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? M1riVFI1ODV5MUS3
NALM6 M1nsU2Fxd3C2b4Ppd{BCe3OjeR?= NHPXUXY2yqEQvF2= NE\ldYszPCCq MmjabY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NYXx[FllOjRyNUexOFc>
DU-145 NHPWSoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rlb|AuOTBizsznM41t MlznOFghcMLi MnXVbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MmfFNlM4OzR6MUW=
Nalm-6 NXjvOYN3TnWwY4Tpc44hSXO|YYm= MUexNOKh|ryP NGXk[48yNzJxNDDo MnPZbY5lfWOnczDheZRweGijZ4m= M2nRflI{PjhzMkKz
Reh M{TwR2Z2dmO2aX;uJGF{e2G7 NGm3SWIyOMLizszN MWGxM|IwPCCq M1XhcIlv\HWlZYOgZZV1d3CqYXf5 NX:xZ3FROjN4OEGyNlM>
Nalm-6 MoLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\Xd48xUUN3MDFijNwyOOLCid88US=> MYGyN|Y5OTJ{Mx?=
Reh MnvqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDFUpQ1UUN3MDFijNwyOOLCid88US=> MXeyN|Y5OTJ{Mx?=
HEC1A NIW4e45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3oXHEyODBvNUCwJO69VQ>? NUm0fW5oOjRiaB?= NGewTVlqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NHnuXVUzOzV7NU[5Oy=>
AN3CA MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYK4bpNjOTByLUWwNEDPxE1? Mm\ONlQhcA>? NGTpeJlqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MkXhNlM2QTV4OUe=
HEC50B M1LI[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXkOFNzOTByLUWwNEDPxE1? NGDqXJczPCCq MmnabY5pcWKrdIOgZ4VtdCCpcn;3eIghe2yrZ3j0cJk> M3yxOlI{PTl3Nkm3
HEC1A MVjBdI9xfG:|aYOgRZN{[Xl? MXyyNE8yODBizszN M3PzR|I1KGh? M4rzRYlv\HWlZYOgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M1XHd|I{PTl3Nkm3
AN3CA NUTKcYl5SXCxcITvd4l{KEG|c3H5 M4LOS|IxNzFyMDFOwG0> NIf2N40zPCCq MX3pcoR2[2W|IHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MkjSNlM2QTV4OUe=
HEC50B NHvGT3BCeG:ydH;zbZMhSXO|YYm= NWCwdVJIOjBxMUCwJO69VQ>? NYPyWFFMOjRiaB?= Mnq1bY5lfWOnczDhdI9xfG:|aYOgd4xq\2i2bIm= NU\Vd5ZLOjN3OUW2PVc>
EHEB NH;MXGFCeG:ydH;zbZMhSXO|YYm= NE\ZcoY1OCEQvF2= NHHsTnczPCCq M2G5T4lv\HWlZYOgZZBweHSxc3nz Mln5NlM1QTdyN{W=
A549 NH;5PW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG[wcoZKSzVyPUG1MlfDuTJwODFCuW0> MXKyN|M4PzF7Mh?=
A549 GAPDH-deficient MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETWdmlKSzVyPUG4MlXDuTJwMzFCuW0> NGO4W5AzOzN5N{G5Ni=>
CLL  M{HTbWFxd3C2b4Ppd{BCe3OjeR?= MW[xNEDPxE4EoB?= NFvIe4ozPC17NjDo MnixbY5lfWOnczDhdI9xfG:2aXOgZ4VtdCCmZXH0bC=> MV6yNlIxPzZ6Nh?=
MEC1 NYK2THRKSXCxcITvd4l{KEG|c3H5 NH7CXnYyODEEoN88US=> MX:3NkBp MlPibY5lfWOnczDhdI9xfG:|aYOgd4lodmmoaXPhcpRtgQ>? NHvuUpEzOjF|Mkm3Ny=>
U937  NYTJV45OSXCxcITvd4l{KEG|c3H5 NIq4O24xNjhizszN NEjIbFY1NTR6IHi= M3q1Uolv\HWlZYOgZZBweHSxc3nzJJNtcWeqdHz5 MmTMNlIxPzR5MEC=
U937  M3rSbGFxd3C2b4Ppd{BCe3OjeR?= NYfqTo16OSEQvF2= M4n4e|k3KGh? M2r4S4lv\HWlZYOgZZBweHSxc3nzJJNtcWeqdHz5 NVrTeIkzOjJyMkO1NlM>
Daudi NGXIW2pCeG:ydH;zbZMhSXO|YYm= MUOyNEDPxE1? NITFZlc6PiCq NX;UNFFQcW6mdXPld{BieG:ydH;zbZMhe2yrZ3j0cJk> M1\IeVIzODJ|NUKz
J45.01 NXi0Zm1xSXCxcITvd4l{KEG|c3H5 MV6xJO69VQ>? MXG5OkBp MVnpcoR2[2W|IHHwc5B1d3OrczDzcIlocHSueR?= MonVNlIxOjN3MkO=
RPMI 8226 NITIOWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjQeYhKSzVyPUK1MlnDqMLzwrCzMlch|ryP MYqyNVk1QDJ4NB?=
CEM M3fjN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI[0Z4RKSzVyPUKuOOKhyrIEoECuOEDPxE1? NEDmW4czOTl2OEK2OC=>
Raji NF;SSXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXu1S2hXUUN3ME2wMlQ4yqEEsdMgNE4xPCEQvF2= M2W1O|IyQTR6Mk[0
U937 MnP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDsSFZKSzVyPUCuNlTDqMLzwrCwMlA1KM7:TR?= NXPhb4ZHOjF7NEiyOlQ>
K562 M4[1T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnGV|FiUUN3ME2wMlQ1yqEEsdMgNE4xPSEQvF2= M4XkU|IyQTR6Mk[0
NALM-6 M1rXNmFxd3C2b4Ppd{BCe3OjeR?= M3nhVlExKM7:TdMg MWCyOEBp MXHpcoR2[2W|IHPlcIwh[XCxcITvd4l{KHOuaXfoeIx6 NYHjR4J5OjF4OUmzPFM>
JMV-3 NWjhdWJ1SXCxcITvd4l{KEG|c3H5 NH3J[HoyOCEQvF5CpC=> M{XM[FI1KGh? NILFR2xqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IIPsbYdpfGy7 Mo\ONlE3QTl|OEO=
EHEB MYTGeY5kfGmxbjDBd5NigQ>? NGGxeo02NTVyIN88US=> M4nDflI1KGh? MYjk[YNz\WG|ZYOgdFIyKGW6cILld5Nqd25ic3nncolncWOjboTsfS=> MnTXNlEyPjh|OUG=
JVM-2  MV\GeY5kfGmxbjDBd5NigQ>? NVX0NHYxOzBizszN M4fFV|I1KGh? NVXBSpg4\GWlcnXhd4V{KHB{MTDlfJBz\XO|aX;u MWeyNVE3QDN7MR?=
KBM3/Bu2506 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2KzWGlEOjB;MD62O{DDvU1? M4P6fVIxQTN|NUC5
KBM3/Bu2506 NW[wSm1rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVKxTolxOC54IN88US=> MUSyOEBp Ml7pbY5kemWjc3XzJJRp\SClZXzsJIZz[WO2aX;uJIlvKFNvcHjhd4U> MkPGNlA6OzN3MEm=
MDA-MB-231 NFXhToVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTRwMDFOwG0> MlexNlA1PDd|OUC=
MCF-7 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmGxTWM2OD1zNT6wJO69VQ>? NIrIcHozODR2N{O5NC=>
HLE-B3  MmW4SpVv[3Srb36gRZN{[Xl? M{Ttd|I2KM7:TR?= M4fyeVQ5KGh? NFX6b4ljdG:la4OgTWZPNc7|4pETbY5lfWOnZDDTWGFVOSCyaH;zdIhwenmuYYTpc44h[W6mIFnEU{BmgHC{ZYPzbY9v NILido4zODR|NUG1PC=>
K562 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYS0SHJqPzJiaB?= M4fmUGlEPTB;Mz6zJI5O NVuxclRjOjB|MEexPVg>
BW-225 MmHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjaR|djUUN{ME2xMlM4KMPZMUFijLI5yqEQvF5CpC=> MYGxPFY3OTN6MB?=
OH-65 MmjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nzW2lEOjB;MT6zO{DEnzFy4pkSPOKh|ryPwrC= M3LITlE5PjZzM{iw
GR-145 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWn2SHpZUUN{ME2yMlc1KMPZIEGw5qiTQCBizszNxsA> Ml76NVg3PjF|OEC=
A549 NXr0cIRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|IxRTVwNEigx7chOTEkiKK4JO69VcLi Mn\UNVg3PjF|OEC=
CaSki  MnLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPIUHNKSzJyPUGuN|chy5diMUFijLI4KM7:TdMg NF\J[JoyQDZ4MUO4NC=>
ZMK-1 NYjaeZNCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7tSZVKSzJyPUGuN|chy5diMUFijLI3KM7:TdMg NF\zXncyQDZ4MUO4NC=>
SKW6.4 NXHlRlV{SXCxcITvd4l{KEG|c3H5 NITYdFYxNjBzLUGwJO69VQ>? NV;YbGdMOjRxNEigbC=> MVjpcoR2[2W|IHPlcIwh\GWjdHigbY4h[m:2aDD0bY1mNSCjbnSg[I9{\S1iZHXw[Y5l\W62IH3hco5meg>? M1eySlE5ODl{M{Sw
RPMI 8226 NYPoV3d7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HEUVI1KGh? MX\JR|UxRTFwNUVCpO69VQ>? NH3hfHkyPzl5NkG4Oi=>
MM.1S NVTsXnVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV[0PEBp NXvqPFRPUUN3ME2xN{41QMLizszN NVnyNmgzOTd7N{[xPFY>
MM.1R MmXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\md|Q5KGh? NFHVR3FKSzVyPUOzMlc6KM7:TR?= MnOyNVc6PzZzOE[=
U937 MlfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTNuMkCwJOKyKDV4MDDuUS=> M{TFeVE2QTNyM{[x

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
procaspase-9 / procaspase-3; 

PubMed: 27223263     


Procaspase-9 and procaspase-3 were analyzed by Western blot in CLL cells from three patients after a 48 h-incubation in the absence or presence of 3 μM aphidicolin (APC) with or without fludarabine at 0.3 and 1 μM. β-Actin served as a loading control.

p-p53 / p53; 

PubMed: 27223263     


(A–B) CLL cells from 3 different patients were incubated for 24 h with fludarabine at the indicated concentrations in the absence or presence of 3 μM aphidicolin (APC). Phosphorylation of p53 at Ser-15 and total p53 were analyzed by Western blot. Data sho䲧疝Ỵ疞㧀疜膉痘 瘿�෋ᾰƌ෋à 㺣痖帉痖Ѐ瑖堘𢡄빢᎒෋à鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒

STAT1; 

PubMed: 26677135     


Representative western blot analysis of STAT1 in RAW 264.7 cells treated with STAT1 inhibitor fludarabine (Flu) for 24 h.

27223263 26677135
Immunofluorescence
α-SMA / Vimentin; 

PubMed: 28322315     


FLU (50 μM) reduces the expression of α-SMA and Vimentin protein in primary mouse activated HSCs (Hepatic Stellate Cells).

28322315
Growth inhibition assay
Cell viability ; 

PubMed: 24956101     


CLL cells RPMI/0.1% FBS were cultured on 0.5% BSA or 150 nM MMP-9 for 1 h prior to adding the indicated concentrations of fludarabine (Fluda). After 48 h (Fluda) cell viability was determined by flow cytometry using FITC-Annexin V and PI.

24956101
In vivo Tumors treated with PBS grow rapidly to approx-imately 10-fold their initial volume in 25 day, whereas, the tumors in the Fludarabine at 40 mg/kg increase less than 5-fold. A significant antitumor effect of 40 mg/kg Fludarabine on RPMI8226 tumor growth is demonstrated. RPMI8226 tumors treated with 40 mg/kg Fludarabine at day 10 increase apoptotic nuclei. Fludarabine is effective in suppressing RPMI8226 myeloma xenografts in SCID mice. [1]

Protocol

Cell Research:

[1]

- Collapse
  • Cell lines: Dexamethasone-sensitive (MM.1S) and -resistant (MM.1R) human MM cell lines, RPMI8226 and U266 cell lines
  • Concentrations: 2 μg/mL
  • Incubation Time: 24 hours
  • Method:

    After treated with Fludarabine or control, dexamethasone-sensitive (MM.1S) and -resistant (MM.1R) human MM cell lines, RPMI8226 and U266 cell lines (5 × 105 cells) are washed twice in phosphate-buffered saline (PBS) and fixed with 70% ice-cold ethanol, then centrifuged and suspended in PBS containing 100 μg/mL RNase A. After incubated for 30 minutes at 37 ºC, samples are resuspended in 25 μg/mL propidium iodide. Flow cytometry is performed on a FACSCalibur automated system. Apoptosis is determined by Annexin V-FITC apoptosis detection kit, according to the manufacturer's instructions. For TUNEL (terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling) assay, cells are analyzed by flow cytometry using the in situ cell death detection kit.


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: Severe combined immunodeficient (SCID) mice bearing RPMI 8226 cells
  • Formulation: PBS
  • Dosages: 40 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 57 mg/mL (199.83 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% propylene glycol, 5% Tween 80, 65% D5W
For best results, use promptly after mixing.
30 mg/mL (suspension)

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 285.23
Formula

C10H12FN5O4

CAS No. 21679-14-1
Storage powder
in solvent
Synonyms FaraA, Fludarabinum

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03832127 Not yet recruiting Drug: 18F-Fludarabine Myeloma Nantes University Hospital|Cyceron April 1 2019 Phase 1
NCT03348033 Enrolling by invitation Biological: Chronic Myeloid Leukemia + NK cell Chronic Myeloid Leukemia Hospital de Clinicas de Porto Alegre March 2019 Phase 1|Phase 2
NCT03613532 Recruiting Drug: Venetoclax|Drug: Fludarabine|Drug: Busulfan Acute Myeloid Leukemia (AML)|Myelodysplastic Syndrome (MDS)|Chronic Myelomonocytic Leukemia (CMML)|MDS/Myeloproliferative Neoplasm-unclassifiable (MDS/MPN-unclassifiable)|Hematopoietic Stem Cell Transplant Jacqueline Garcia MD|Dana-Farber Cancer Institute October 1 2018 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    how to re-suspend and deliver the inhibitor for in vivo experiments?

  • Answer:

    For S1491, Fludarabine, we tested a vehicle: 30% Propylene glycol, 5% Tween 80, 65% D5W that you can resuspend the compound in at up to 30mg/ml. It's a suspension and can only be given via oral gavage.

STAT Signaling Pathway Map

Related STAT Products

Tags: buy Fludarabine | Fludarabine supplier | purchase Fludarabine | Fludarabine cost | Fludarabine manufacturer | order Fludarabine | Fludarabine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID